Abstract:Target Audience Radiologists, urologist, radiotherapy physicians and MR technologists Purpose Blood oxygen level dependent (BOLD) MRI is a non-invasive method that can assess hypoxia in prostate gland, through utilizing the endogenous contrast generated by paramagnetic deoxyhemoglobin. R2* quantification by BOLD has been shown to be sensitive to oxygenation status and accordance to hypoxia measured by immunohistochemical staining with pimonidazole and Eppendorf pO2 microelectrode in prostate cancer. Tumor hypoxia and its downstream effects remain of considerable interest for clinicians due to its negative impact on response to various cancer therapies and promotion of metastasis. Meanwhile the perfusion information is the key factor that influence R2* interpretation in acute hypoxia measured by BOLD. Therefore the purpose of the study was to investigate the ability of R2* by BOLD MRI in staging of prostate tumor, and compared R2* with blood flow (BF) from ASL. Methods The local ethics committee approved the study and 40 patients (mean 73±9 years; range 50-86 years) with pathologically confirmed prostate cancer were recruited. The patients were classified into three stage groups based on the American Joint Committee on Cancer (AJCC) staging system for prostate cancer, including T2 (n=9), T3 (n=17), T4 (n=14). MR examinations were performed on a clinical 3.0T MR scanner (Signa HD; GE Healthcare, Milwaukee, Wisconsin, USA) with the 8-channel pelvic phased-array coil before biopsy. The BOLD MRI was performed with multiple-echo spoiled gradient recalled echo (SPGR) protocol prescribed with12 time echoes (TEs), as well as with the following parameters: TR= 100 ms; TE= 6.8–32.1ms; FA=45°; bandwidth= 31.25 kHz; matrix= 128×128; FOV= 24 cm2; section thickness/gap= 5/0mm; section number= 16; NEX= 2. The ASL protocol was performed with FAIR-SSFSE sequence, with parameters (TI=1000msec; TR/TRM0= 3500/6000ms; flip angle = 90°; FOV=24 cm2; slice thickness=5mm and phases=8). The regions of interest (ROIs) were placed in the prostate cancerous zone (including the whole prostate cancer area), the normal prostate peripheral zone and periprostatic muscle, avoiding the areas of necrosis, calcification, hemorrhage and air or movement artifacts. The average R2* and blood flow (BF) in these regions for each patient was computed respectively. The One-Way AVONA analysis was conducted to compare the R2* among the groups. The correlation analysis were also performed between R2* and BF in cancerous zones. Results There is a significant drop of R2* along with the prostate cancer upstaged detected via BOLD MRI (26.3±6.2 s, 24.7±5.6 s and 20.4±5.8 s) (P<0.05, AVONA analysis) (Figure 1), and mean R2* in the normal prostate peripheral zone and periprostatic muscle were 14.0±5.6 s and 38.3±5.9 s. Inverse correlation between R2* and BF(r= -0.384, P = .014) were found in cancerous zones. Discussion This study demonstrates that BOLD MRI can be used to evaluate hypoxia in prostate cancer and differentiate the three clinical stages. However a decreasing of hypoxia was observed with increasing clinical stage from BOLD measurements involved prostate cancer. The negative correlation between R2* and blood flow that was observed suggests that R2* values in patients with prostate cancer may be highly dependent on blood oxygenation. Conclusion BOLD MR imaging is a potentially useful in vivo imaging technique to detect hypoxia in the prostate cancer. But it is needed to take blood oxygenation information into consideration when staging of prostate cancer, as it is highly dependent on blood flow.

Towards tumour hypoxia imaging: Incorporating relative oxygen extraction fraction mapping of prostate with multi‐parametric quantitative MRI on a 1.5T MR‐linac

Retrospective T2 Quantification from Conventional Weighted MRI of the Prostate Based on Deep Learning

Positron Emission Tomography Imaging of Tumor Hypoxia

Quantitative longitudinal mapping of radiation-treated prostate cancer using MR fingerprinting with radial acquisition and subspace reconstruction

Optimization and validation of low-field MP2RAGE T1 mapping on 0.35T MR-Linac: Toward adaptive dose painting with hypoxia biomarkers

Quantitative hypoxia imaging for treatment planning of radiotherapy

Role of R 2 * with BOLD MRI in the Staging of Prostate Cancer

Advances in PET and MRI imaging of tumor hypoxia

A Near-Infrared Phosphorescent Nanoprobe Enables Quantitative, Longitudinal Imaging of Tumor Hypoxia Dynamics During Radiotherapy.

Implementation of Oxygen Enhanced Magnetic Resonance Imaging (OE-MRI) and a Pilot Genomic Study of Hypoxia in Bladder Cancer Xenografts

Distortion-Free Diffusion MRI using an MRI-Guided Tri-Cobalt 60 Radiotherapy System: Sequence Verification and Preliminary Clinical Experience.

Quantifying Reoxygenation in Pancreatic Cancer During Stereotactic Body Radiotherapy

Combined Oxygen-enhanced MRI and perfusion imaging detect hypoxia modification from banoxantrone and atovaquone and track their differential mechanisms of action

Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats

Oxygen extraction fraction mapping with multi-parametric quantitative BOLD MRI: Reduced transverse relaxation bias using 3D-GraSE imaging

Bioparameter-directed nanoformulations as MRI CAs enable the specific visualization of hypoxic tumour

Quantitative hypoxia mapping using a self-calibrated activatable nanoprobe

Radiosensitizing oxygenation changes in murine tumors treated with VEGF-ablation therapy are measurable using oxygen enhanced-MRI (OE-MRI)

Supplementary Data from A Near-Infrared Phosphorescent Nanoprobe Enables Quantitative, Longitudinal Imaging of Tumor Hypoxia Dynamics During Radiotherapy

Development of a PET/EPRI combined imaging system for assessing tumor hypoxia

Rapid multicontrast brain imaging on a 0.35T MR‐linac